Added to YB: 2026-10-09
Pitch date: 2026-10-04
GNLX [bullish]
Genelux Corporation
-9.02%
current return
Author Info
No bio for this author
Company Info
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Market Cap
$113.8M
Pitch Price
$2.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.72
P/E
-2.95
EV/Sales
12.2K
Sector
Biotechnology
Category
growth
M&A Hunter Portfolio Update: Tier 3 Core Convictions (Under $10) - Genelux Corporation
GNLX (hold): Genelux, at $2.59, offers an oncolytic-virus and combination-immuno-oncology thesis: a larger oncology company could use its virus platform to improve a checkpoint inhibitor, chemotherapy or another treatment combination. However, oncolytic viruses have not consistently produced broad, repeatable commercial franchises; the asset must demonstrate a clear clinical combination advantage before a prospective buyer is likely to view it as more than an experimental add-on.
Read full article (1 min)